Bausch & Lomb
This article was originally published in The Gray Sheet
December launch is planned for the firm's 25-gauge entry site alignment (ESA) device for use with the Millennium TSV25 system for transconjunctival standard vitrectomy, following 510(k) clearance of the component, announced Oct. 29. The system is used to correct retinal detachments, macular degeneration and diabetic eye diseases with incisions about half the size of standard incisions, according to B&L. Separately, the firm has agreed to license worldwide rights to Largo, Florida-based Unilens Corp.'s cast-molded, multifocal soft contact lens design. Under the agreement, B&L will develop, manufacture and market the device for frequent replacement, and pay a royalty ranging from 3-5% of sales. Distribution will begin within the next year, pending FDA approval...
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.